Marching Forward in Atopic Dermatitis
Digging Deep on Shared Decision-Making
Meeting Slides
Guidelines
Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.
Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.
Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349.
Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.
Patient Resources
International Eczema Council
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.
National Eczema Association
The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education.
Clinical Assessment Tools
Children’s Dermatology Life Quality Index (CDLQI)
CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).
Eczema Area and Severity Index (EASI)
EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe). (Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18).
Investigator Global Assessment (IGA)
The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials. (Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294).
Patient-Oriented Eczema Measure (POEM)
The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).
Scoring Atopic Dermatitis (SCORAD)
SCORAD is a clinical tool used to assess the extent and severity of eczema. (Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.)
Suggested Readings
Atopic Dermatitis Overview and Pathogenesis
Atopic dermatitis endotypes and implications for targeted therapeutics.
Czarnowicki T, et al. J Allergy Clin Immunol. 2019;143(1):1-11.
Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Pathogenesis of atopic dermatitis.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Expression patterns of atopic eczema and respiratory illnesses in a high-risk birth cohort.
Singh AM, et al. J Allergy Clin Immunol. 2010:125(2):491-493.
Patient Burden and Comorbidities
Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march.
Holm JG, et al. Arch Dermatol Res. 2019;311(3):173-182.
The atopic march and atopic multimorbidity: many trajectories, many pathways.
Paller AS, et al. J Allergy Clin Immunol. 2019;143(1):46-55.
Association between atopic dermatitis and suicidality: a systematic review and meta-analysis
Sandhu JK, et al. JAMA Dermatol. 2019;155(2):178-187.
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults.
Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121(5):604-612
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Management of Atopic Dermatitis
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Application of moisturizer to neonates prevents development of atopic dermatitis.
Horimukai K, et al. J Allergy Clin Immunol. 2014;134(4):824-830.
New and emerging therapies for pediatric atopic dermatitis.
Nguyen HL, et al. Pediatric Drugs. 2019;21(4):239-260.
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.
Silverberg JI. J Allergy Clin Immunol. 2019 Aug 23 pii: S0091-6749(19)31099-1. [Epub ahead of print].
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Simpson EL, et al. J Am Acad Dermatol. 2018;78(5):863-871.
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A, et al. J Allergy Clin Immunol. 2019;143(1):135-141.
Interactive PresentationClinical Insights Into Atopic Dermatitis Pathogenesis
This short video discusses the pathophysiology of atopic dermatitis, illustrating how it is a disease of both barrier dysfunction and Th2-driven inflammation. Among Th2 cytokines, IL-4 and IL-13 have demonstrated a key role in AD pathogenesis, which has led to the development of a human monoclonal antibody against IL-4Rα for the treatment of moderate-to-severe disease.
Digging Deep on Shared Decision-Making
Relevant Resources
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Looking Beyond Barriers to Optimize Therapy
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Debates and Discussions About Pustular Disease Subtypes
Collaborative Care for Better Patient Outcomes
Improving Patient Outcomes Through Shared Clinical Decision Making
Clinical Resource Center
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A Focus on Exacerbation Prevention
Best Practices for Primary Care
Evolving Best Practices for Patient Management
Pathophysiology, Multimodal Management, and Shared Clinical Decision Making
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Evolving Best Practices for Pediatric Patients
A Case-Based Update
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
An Interactive Educational Journey
Test Your Mastery!
